Over 1,000 Chemotherapy Protocols And Counting

Phase 3, multicenter, randomized, controlled trial (KATHERINE) HER2-positive early breast cancer with residual invasive cancer after neoadjuvant therapy T-DM1 vs. trastuzumab (14 c

24 Jan

GastroEsophageal Cancer

New Reference: Periop FLOT in Esophageal Cancer

Phase 3, multicenter, randomized, controlled trial (ESOPEC) Esophageal or GE junction adenoCa, cT1cN+, cT2–4a cN+, or cT2–4a cN0 FLOT (perioperative chemotherapy) vs. preoperat

20 Jan

Breast Cancer

New Drug: Datopotamab Deruxtecan for HR+, her2 Neg Breast Cancer

Phase 3, open-label, randomized study (TROPION-Breast01) Inoperable or metastatic HR+/HER2– breast cancer, previously treated with 1 or 2 lines of chemotherapy in the inoperable/

19 Jan

Mantle cell lymphoma

New Protocol: Acalabrutinib with R-Bendamustine for Mantle Cell Lymphoma

Randomized, double-blind, placebo-controlled, multicenter trial (ECHO) Previously untreated Mantle Cell Lymphoma (MCL) who were ineligible for transplant (N=598) Acalabrutinib + R-

6 Dec

Non-Small Cell Lung CancerPancreatic Cancer

New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer

Multi-center, open lavel study (eNRGy) NRG1 fusion positive NSCLC (n=64) and pancreatic adenocarcinoma (n=30) with disease progression after standard therapy

11 Nov

GastroEsophageal Cancer

New Drug: Zolbetuximab with FOLFOX for Gastric and GE Junction Cancer

Phase 3, multicenter, randomized, double-blind trial (SPOTLIGHT) Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, CLDN18.2-positive,

30 Sep

Non-Small Cell Lung Cancer

New Indication: Osimertinib after Chemoradiotherapy in NSCLC

Phase 3, double-blind, placebo-controlled trial (LAURA) Locally advanced, unresectable stage III NSCLC with EGFR exon 19 deletion or L858R mutation after chemoradiation Osimertinib

27 Aug

Non-Small Cell Lung Cancer

New Drug: Lazertinib for EGFR mutated NSCLC

Type: Phase 3, international, randomized trial Population: Patients with previously untreated EGFR-mutated advanced NSCLC (Ex19del or L858R) Treatment: Amivantamab–lazertinib vs.

24 Jun

Small Cell Lung Cancer

New Drug: Tarlatamab for SCLC

Phase 2, open-label (DeLLphi-301) Relapsed/refractory to platinum-based therapy Advanced SCLC Tarlatamamab 10 or 100 mg => Final dose selected as 10 mg

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries